CONCORDBIO2023-07-012023-09-30 CONCORDBIO2023-07-012023-09-30 CONCORDBIO2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member CONCORDBIO2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member CONCORDBIO2023-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543960 CONCORDBIO NA Concord Biotech Limited Equity 2023-04-01 2024-03-31 2023-11-08 2023-10-25 INR Lakhs Half yearly 11:00:00 15:00:00 2023-11-08 2023-11-08 true Cash Flow Indirect Not applicable Single segment Pharmaceuticals 2023-07-01 2023-09-30 Unaudited Consolidated 2623456000.00 81265000.00 2704721000.00 420008000.00 104753000.00 3924000.00 301658000.00 8406000.00 132953000.00 601228000.00 1572930000.00 1131791000.00 0.00 1131791000.00 277558000.00 9291000.00 286849000.00 0.00 844942000.00 0.00 0.00 0.00 -34743000.00 810198000.00 3231000.00 813429000.00 810199000.00 0.00 3231000.00 0.00 104616000.00 1 7.74 7.74 0.00 0.00 7.74 7.74 Notes to the statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2023: 1. The Company's equity shares have been listed on National Stock Exchange ( NSE ) and on BSE Limited ( BSE ) on August 18, 2023 by completing Initial Public Offering through offer for sale of 2,09,25,652 equity shares of face value of Rs. 1 each at an issue price of Rs. 741 per equity share by selling shareholder. 2. The above consolidated unaudited financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on November 08, 2023. The Statutory Auditors have carried out limited review of the financial results for the quarter and half year ended on September 30, 2023. 3. The total initial public offer expenses are entirely allocated to the selling shareholders except for the listing fees which has been solely borne by the Company. 4. The consolidated financial results for the quarter ended September 30, 2022 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the financial results for this period provide a true and fair view of the Company's affairs. 5. The Company and its joint venture are engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - Operating Segments . 6. The consolidated financial results for the half year ended September 30, 2022 have been extracted from the audited Special Purpose Consolidated Interim Balance Sheet as at September 30, 2022, Statement of Profit and loss for the six months ended September 30, 2022 and Interim Cash Flow Statement for the six months ended September 30, 2022 which were prepared for IPO fillings. Single segment 2023-04-01 2023-09-30 Unaudited Consolidated 4571734000.00 147810000.00 4719543000.00 814766000.00 220707000.00 -102802000.00 584199000.00 15938000.00 263365000.00 1141457000.00 2937630000.00 1781913000.00 0.00 1781913000.00 440558000.00 11710000.00 452268000.00 0.00 1329645000.00 0.00 0.00 0.00 25497000.00 1355142000.00 2451000.00 1357593000.00 0.00 0.00 2451000.00 0.00 104616000.00 1 12.95 12.95 0.00 0.00 12.95 12.95 Other expenses 601228000.00 Other expenses 1141457000.00 0.00 5857940000.00 1877253000.00 0.00 0.00 5404000.00 0.00 0.00 0.00 12368000.00 0.00 0.00 76608000.00 88976000.00 124210000.00 7953782000.00 2198571000.00 1501951000.00 2670436000.00 60780000.00 687947000.00 0.00 264962000.00 5186075000.00 0.00 171827000.00 7556473000.00 0.00 0.00 15510255000.00 104616000.00 13438471000.00 13543087000.00 13543087000.00 0.00 26715000.00 26715000.00 19054000.00 246930000.00 292699000.00 187298000.00 761157000.00 622526000.00 1570980000.00 74400000.00 29089000.00 1674469000.00 1967168000.00 15510255000.00 15938000.00 -75424000.00 52985000.00 0.00 74691000.00 0.00 0.00 -17165000.00 0.00 -396600000.00 0.00 36732000.00 0.00 263365000.00 0.00 -52951000.00 0.00 -77039000.00 0.00 -18993000.00 0.00 16612000.00 0.00 -45223000.00 0.00 -16497000.00 2455000.00 -27821000.00 0.00 -298158000.00 1483755000.00 0.00 0.00 0.00 313033000.00 0.00 1170723000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 582000.00 299161000.00 3800071000.00 3869755000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2382000.00 0.00 78683000.00 0.00 -287199000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 125058000.00 0.00 0.00 714529000.00 14704000.00 0.00 -3445000.00 -857736000.00 25787000.00 0.00 25787000.00 34993000.00 60780000.00 4321000.00 3280000.00 1091000.00 829000.00